The Microbiome and Tuberculosis: Early Evidence for Cross Talk
Tuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and host geneti...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2018-09-01
|
Series: | mBio |
Subjects: | |
Online Access: | https://doi.org/10.1128/mBio.01420-18 |
id |
doaj-2dc1a7c593df403b821e5e5819edfb75 |
---|---|
record_format |
Article |
spelling |
doaj-2dc1a7c593df403b821e5e5819edfb752021-07-02T01:48:20ZengAmerican Society for MicrobiologymBio2150-75112018-09-0195e01420-1810.1128/mBio.01420-18The Microbiome and Tuberculosis: Early Evidence for Cross TalkSivaranjani NamasivayamAlan SherMichael S. GlickmanMatthew F. WippermanTuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and host genetics, the variable pathogenesis of TB in infected individuals remains poorly understood.Tuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and host genetics, the variable pathogenesis of TB in infected individuals remains poorly understood. During the past two decades, it has become clear that the microbiota—the trillion organisms that reside at mucosal surfaces within and on the body—can exert a major influence on disease outcome through its effects on host innate and adaptive immune function and metabolism. This new recognition of the potentially pleiotropic participation of the microbiome in immune responses has raised the possibility that the microbiota may influence M. tuberculosis infection and/or disease. Similarly, treatment of TB may alter the healthy steady-state composition and function of the microbiome, possibly affecting treatment outcome in addition to other host physiological parameters. Herein, we review emerging evidence for how the microbiota may influence the transition points in the life cycle of TB infection, including (i) resistance to initial infection, (ii) initial infection to latent tuberculosis (LTBI), (iii) LTBI to reactivated disease, and (iv) treatment to cure. A major goal of this review is to frame questions to guide future scientific and clinical studies in this largely unexplored but increasingly important area of TB research.https://doi.org/10.1128/mBio.01420-18antibioticsmicrobiometuberculosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sivaranjani Namasivayam Alan Sher Michael S. Glickman Matthew F. Wipperman |
spellingShingle |
Sivaranjani Namasivayam Alan Sher Michael S. Glickman Matthew F. Wipperman The Microbiome and Tuberculosis: Early Evidence for Cross Talk mBio antibiotics microbiome tuberculosis |
author_facet |
Sivaranjani Namasivayam Alan Sher Michael S. Glickman Matthew F. Wipperman |
author_sort |
Sivaranjani Namasivayam |
title |
The Microbiome and Tuberculosis: Early Evidence for Cross Talk |
title_short |
The Microbiome and Tuberculosis: Early Evidence for Cross Talk |
title_full |
The Microbiome and Tuberculosis: Early Evidence for Cross Talk |
title_fullStr |
The Microbiome and Tuberculosis: Early Evidence for Cross Talk |
title_full_unstemmed |
The Microbiome and Tuberculosis: Early Evidence for Cross Talk |
title_sort |
microbiome and tuberculosis: early evidence for cross talk |
publisher |
American Society for Microbiology |
series |
mBio |
issn |
2150-7511 |
publishDate |
2018-09-01 |
description |
Tuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and host genetics, the variable pathogenesis of TB in infected individuals remains poorly understood.Tuberculosis (TB) is an ancient infectious disease of humans that has been extensively studied both clinically and experimentally. Although susceptibility to Mycobacterium tuberculosis infection is clearly influenced by factors such as nutrition, immune status, and both mycobacterial and host genetics, the variable pathogenesis of TB in infected individuals remains poorly understood. During the past two decades, it has become clear that the microbiota—the trillion organisms that reside at mucosal surfaces within and on the body—can exert a major influence on disease outcome through its effects on host innate and adaptive immune function and metabolism. This new recognition of the potentially pleiotropic participation of the microbiome in immune responses has raised the possibility that the microbiota may influence M. tuberculosis infection and/or disease. Similarly, treatment of TB may alter the healthy steady-state composition and function of the microbiome, possibly affecting treatment outcome in addition to other host physiological parameters. Herein, we review emerging evidence for how the microbiota may influence the transition points in the life cycle of TB infection, including (i) resistance to initial infection, (ii) initial infection to latent tuberculosis (LTBI), (iii) LTBI to reactivated disease, and (iv) treatment to cure. A major goal of this review is to frame questions to guide future scientific and clinical studies in this largely unexplored but increasingly important area of TB research. |
topic |
antibiotics microbiome tuberculosis |
url |
https://doi.org/10.1128/mBio.01420-18 |
work_keys_str_mv |
AT sivaranjaninamasivayam themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT alansher themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT michaelsglickman themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT matthewfwipperman themicrobiomeandtuberculosisearlyevidenceforcrosstalk AT sivaranjaninamasivayam microbiomeandtuberculosisearlyevidenceforcrosstalk AT alansher microbiomeandtuberculosisearlyevidenceforcrosstalk AT michaelsglickman microbiomeandtuberculosisearlyevidenceforcrosstalk AT matthewfwipperman microbiomeandtuberculosisearlyevidenceforcrosstalk |
_version_ |
1721344243863126016 |